Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Epkinly (epcoritamab-bysp)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AbbVie, Genmab

Drug class:

CD20 inhibitor, CD3 agonist

Related drugs:

rituximab (174)

obinutuzumab (68)

ublituximab-xiiy (7)

rituximab-pvvr (6)

rituximab-abbs (6)

rituximab/hyaluronidase (5)

Rixathon (rituximab biosimilar) (4)

ibritumomab tiuxetan (3)

mosunetuzumab-axgb (2)

rituximab-arrx (2)

glofitamab-gxbm (1)

TQB2303 (rituximab biosimilar) (1)

odronextamab (1)

Ritucad (rituximab biosimilar) (1)

AcellBia (rituximab biosimilar) (0)

zuberitamab (0)

Avetux (rituximab biosimilar) (0)

BI 695500 (rituximab biosimilar) (0)

CIMAbior (rituximab biosimilar) (0)

DI Leu16 IL-2 (0)

GB241 (rituximab biosimilar) (0)

Halpryza (rituximab biosimilar) (0)

Hanlikon (rituximab biosimilar) (0)

Reditux (rituximab biosimilar) (0)

JHL1101 (rituximab biosimilar) (0)

Kikuzubam (rituximab biosimilar) (0)

MK-8808 (rituximab biosimilar) (0)

MabionCD20 (rituximab biosimilar) (0)

Mabtas (rituximab biosimilar) (0)

Novex (rituximab biosimilar) (0)

ocrelizumab (0)

Retuxira (rituximab biosimilar) (0)

SAIT101 (rituximab biosimilar) (0)

SIBP-02 (rituximab biosimilar) (0)

TG20 (rituximab biosimilar) (0)

blinatumomab (52)

elranatamab-bcmm (8)

tebentafusp-tebn (7)

tarlatamab-dlle (4)

talquetamab-tgvs (2)

teclistamab-cqyv (2)

JNJ-63898081 (1)

CD30 biAb-AATC (0)

JNJ-63709178 (0)

JNJ-67571244 (0)

linvoseltamab (0)

PF-06671008 (0)

PF-07062119 (0)

PF-07260437 (0)

catumaxomab (0)

UMG2-CD3 BTCE (0)

Undisclosed HER2Bi-armed ATC (0)

activated CIK and bispecific antibody (0)

activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)

ABBV-383 IV (0)

huCD33-BsAb (0)

›

No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	epcoritamab-bysp Sensitive: A1 - Approval epcoritamab-bysp Sensitive : A1	epcoritamab-bysp Sensitive: A1 - Approval epcoritamab-bysp Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	epcoritamab-bysp Sensitive: A1 - Approval epcoritamab-bysp Sensitive : A1	epcoritamab-bysp Sensitive: A1 - Approval epcoritamab-bysp Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	epcoritamab-bysp Sensitive: A1 - Approval epcoritamab-bysp Sensitive : A1	epcoritamab-bysp Sensitive: A1 - Approval epcoritamab-bysp Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	epcoritamab-bysp Sensitive: C2 – Inclusion Criteria epcoritamab-bysp Sensitive : C2	epcoritamab-bysp Sensitive: C2 – Inclusion Criteria epcoritamab-bysp Sensitive : C2
CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	epcoritamab-bysp Sensitive: C2 – Inclusion Criteria epcoritamab-bysp Sensitive : C2	epcoritamab-bysp Sensitive: C2 – Inclusion Criteria epcoritamab-bysp Sensitive : C2
CD20 positive	Mantle Cell Lymphoma	CD20 positive	Mantle Cell Lymphoma	epcoritamab-bysp Sensitive: C3 – Early Trials epcoritamab-bysp Sensitive : C3	epcoritamab-bysp Sensitive: C3 – Early Trials epcoritamab-bysp Sensitive : C3
CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	rituximab + lenalidomide + epcoritamab-bysp Sensitive: C3 – Early Trials rituximab + lenalidomide + epcoritamab-bysp Sensitive : C3	rituximab + lenalidomide + epcoritamab-bysp Sensitive: C3 – Early Trials rituximab + lenalidomide + epcoritamab-bysp Sensitive : C3
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	epcoritamab-bysp Sensitive: C3 – Early Trials epcoritamab-bysp Sensitive : C3	epcoritamab-bysp Sensitive: C3 – Early Trials epcoritamab-bysp Sensitive : C3
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	epcoritamab-bysp Sensitive: C3 – Early Trials epcoritamab-bysp Sensitive : C3	epcoritamab-bysp Sensitive: C3 – Early Trials epcoritamab-bysp Sensitive : C3
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	epcoritamab-bysp Sensitive: C3 – Early Trials epcoritamab-bysp Sensitive : C3	epcoritamab-bysp Sensitive: C3 – Early Trials epcoritamab-bysp Sensitive : C3
CD20 expression	Non-Hodgkin’s Lymphoma	CD20 expression	Non-Hodgkin’s Lymphoma	lenalidomide + epcoritamab-bysp Sensitive: D – Preclinical lenalidomide + epcoritamab-bysp Sensitive : D	lenalidomide + epcoritamab-bysp Sensitive: D – Preclinical lenalidomide + epcoritamab-bysp Sensitive : D